Abstract 60P
Background
Using liquid-based next generation sequencing (NGS) to detect circulating tumor DNA (ctDNA) and understanding genetic profiling has become more accessible recently. However, there is still limited prospective data in Asian breast cancer patients. This study is using Guardant360 to identify the genetic landscape of patients with recurrent breast cancer (BC) and de novo stage IV metastatic BC in an Asian population and to demonstrate genetic profile changes at disease progression.
Methods
Patients with either recurrent BC or de novo stage IV BC underwent both tissue-based NGS and liquid-based NGS before systemic therapy, and had liquid-based NGS done at PD. All patients were recruited from MacKay Memorial hospital from Jan 2020 to Dec 2021. The study was suspended in Jan 2022 due to restructuring of the sponsor’s organisation. Oncomine Comprehensive Assay was used for tissue based NGS, and Guardant360 was used for liquid based NGS.
Results
There were 44 patients (age range: 37-90 years old) recruited in the study, with 55 liquid samples (44 baseline and 11 PD samples), and 46 primary tissue samples or metastatic tissue samples in total. All the 46 tissue samples and all the 55 liquid samples were successfully sequenced. Out of the 44 liquid samples prior systemic therapy, ctDNA were detected in 84% (n=37) of the samples. Among of these 37 ctDNA positive samples, 64% of them have targetable alterations detected, including PIK3CA (31.8%, n=14), BRCA2 (20.5%, n=9), BRCA1 (9.1%, n=4), ERBB2 (4.6%, n=2), ESR1 (4.6%, n=2), FGFR2 amplification (4.6%, n=2), AKT1 (2.3%, n=1), and FGFR1 amplification (2.3%, n=1). In the study, we observed that higher percentage BRCA2/BCRA1 mutation was detected by liquid biopsy. A total of 31 patients underwent liquid and tissue NGS. We observed a high concordance in ESR1 alteration with 100%. Of the 12 patients with PIK3CA mutation detected in liquid and/or tissue, 8 were detected in both tissue and liquid, 2 detected in tissue alone and 2 detected in liquid alone.
Conclusions
Liquid-based NGS can be applied in clinical practice to identified clinically important mutations in Asian patients with recurrent breast cancer (BC) and de novo stage IV metastatic BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P-S. Yang.
Funding
Yonglin Foundation, Taipei, Taiwan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract